{{Rsnum
|rsid=6555546
|Gene=LOC729506
|Chromosome=5
|position=8440791
|Orientation=plus
|GMAF=0.2658
|Gene_s=SNORD19B
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 9.7 | 43.4 | 46.9
| HCB | 0.0 | 2.9 | 97.1
| JPT | 0.0 | 0.0 | 100.0
| YRI | 39.5 | 46.3 | 14.3
| ASW | 22.8 | 56.1 | 21.1
| CHB | 0.0 | 2.9 | 97.1
| CHD | 0.0 | 3.7 | 96.3
| GIH | 7.9 | 39.6 | 52.5
| LWK | 30.9 | 52.7 | 16.4
| MEX | 1.7 | 36.2 | 62.1
| MKK | 25.6 | 46.8 | 27.6
| TSI | 12.7 | 31.4 | 55.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs6555546
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.000008. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109440
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6555546
|overall_frequency_n=40
|overall_frequency_d=128
|overall_frequency=0.3125
|n_genomes=28
|n_genomes_annotated=0
|n_haplomes=37
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}